Combination Chemotherapy for Advanced Colorectal Cancer A Pilot Study
- 1 February 1986
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 9 (1) , 31-34
- https://doi.org/10.1097/00000421-198602000-00009
Abstract
Twenty-three patients with advanced colorectal carcinoma, mostly with liver and lung metastases and measurable disease, were treated with mitomycin-C 20 mg/m2 I.V. and vincristine 1.2 mg/m2 I.V. every 6 weeks, and cisplatinum 50 mg/m2 I.V. and 5-fluorouracil 1,000 mg/m2/24 hours I.V. continuous infusion for 96 hours every 3 weeks based upon the hypothesis that cisplatinum may potentiate the antitumor activity of antimetabolites and alkylating agents. Five patients had received prior chemotherapy and six had received prior radiotherapy, with one of these patients receiving both. One complete and 10 partial responses were observed, with an overall response rate of 48% (90% confidence interval 30-70%). The toxicity was manageable. A possible potentiating effect of cisplatinum is suggested in this first attempt in the treatment of colorectal cancer, and warrants further exploration.This publication has 6 references indexed in Scilit:
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982
- Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil vincristine and streptozotocin (MOF-strep)Cancer, 1980
- EFFECTS OF CIS-DICHLORODIAMMINEPLATINUM(II) ON HUMAN-COLON CARCINOMA-CELLS INVITRO1979
- 5FU infusion with mitomycin-C versus 5FU infusion with methyl-CCNU in the treatment of advanced colon cancer.A southwest oncology group studyCancer, 1978
- A phase III study comparing the clinical utility of four regimens of 5-Fluorouracil.A preliminary reportCancer, 1977
- Fluorouracil, methyl-ccnu and vincristine in cancer of the colonCancer, 1976